COLL Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of -380280%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Altimmune, Inc.'s return on equity of -56.24%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling upside risk potential of 5.11%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 391.69%. Given that Altimmune, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Altimmune, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.037, suggesting its less volatile than the S&P 500 by 96.298%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are larger than Altimmune, Inc. quarterly revenues of $5K. Collegium Pharmaceutical, Inc.'s net income of $31.5M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.82x while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.32x versus 14,336.40x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 35.57%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling upside risk potential of 5.11%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 49.35%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Collegium Pharmaceutical, Inc.'s net income of $31.5M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.82x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.32x versus 5.13x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 28.31%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling upside risk potential of 5.11%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 5.87%. Given that Intuitive Surgical, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Collegium Pharmaceutical, Inc.'s net income of $31.5M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.82x while Intuitive Surgical, Inc.'s PE ratio is 74.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.32x versus 21.42x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 34.76%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling upside risk potential of 5.11%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 8.51%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Collegium Pharmaceutical, Inc.'s net income of $31.5M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.82x while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.32x versus 10.01x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.